Johnson & Johnson has entered into a definitive agreement to acquire Proteologix, a Redwood City, California-based biotechnology company specializing in bispecific antibodies for immune-mediated diseases, for $850 million in cash, with the potential for additional milestone payments. The transaction is expected to close by mid-year 2024, pending antitrust clearance and other customary closing conditions.
Proteologix’s portfolio includes PX128, a bispecific antibody targeting IL-13 and TSLP, poised to enter phase 1 development for moderate to severe atopic dermatitis (AD) and moderate to severe asthma. Another key asset is PX130, a bispecific antibody targeting IL-13 and IL-22, currently in preclinical development for moderate to severe AD.
PX128 is designed to inhibit IL-13-mediated Th2 skin inflammation, a crucial pathway in both AD and asthma, as well as TSLP, a mediator of tissue inflammation in these conditions. PX130 similarly inhibits IL-13-mediated Th2 skin inflammation, while also targeting IL-22 to restore the skin barrier and prevent inflammation triggered by environmental allergens. Both antibodies are intended for infrequent dosing, providing convenience that is highly valued by patients. These assets align with Johnson & Johnson’s strategy to build a robust portfolio of differentiated and complementary bispecific therapies.
Beyond PX128 and PX130, the acquisition will enhance Johnson & Johnson’s pipeline with additional bispecific antibody programs targeting a range of diseases, thereby strengthening the company’s capabilities to develop novel bispecific treatments. This acquisition reflects Johnson & Johnson’s commitment to advancing innovative therapeutic solutions for immune-mediated diseases and expanding their impact in the biotechnology sector.
